Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.7.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 10,551 $ 9,589
Marketable securities, current 13,000 39,091
Collaboration receivable 0 1,891
Prepaid expenses and other current assets 623 2,599
Total current assets 24,174 53,170
Property and equipment, net 109 333
Other assets 0 166
Total assets 24,283 53,669
Current liabilities:    
Accounts payable 822 725
Collaboration payable 129 0
Accrued clinical and development expenses 777 6,834
Accrued liabilities 888 3,269
Total current liabilities 2,616 10,828
Warrant liability 1,743 1,864
Deferred rent 36 131
Total liabilities 4,395 12,823
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value: Authorized: 150,000,000 shares at December 31, 2016 and 2015; Issued and outstanding: 71,560,294 and 71,462,059 shares at December 31, 2016 and 2015, respectively 72 71
Additional paid-in capital 373,352 370,236
Accumulated other comprehensive loss (2) (21)
Accumulated deficit (353,534) (329,440)
Total stockholders’ equity 19,888 40,846
Total liabilities and stockholders’ equity $ 24,283 $ 53,669